Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467171 | 0.83 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL8690248 | 0.79 | KMT2A (0.83) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL467287 | 0.78 | SIGMAR1 (0.71) | SIGMAR1 | |
| SCHEMBL467268 | 0.77 | SIGMAR1 (1.00) | SIGMAR1KMT2AMEN1MAPK1HTT | |
| SCHEMBL8274166 | 0.77 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL467139 | 0.77 | SIGMAR1 (0.72) | SIGMAR1 | |
| SCHEMBL466999 | 0.75 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL467427 | 0.74 | SIGMAR1 (0.70) | SIGMAR1POLB | |
| Hydrochloric Acid SCHEMBL1896508 | 0.74 | SIGMAR1 (0.72) | SIGMAR1 | |
| SCHEMBL13246359 | 0.70 | QPCT (0.85) | KMT2AMEN1ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2019-01-10 | — | — | US | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | claimed |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-08-04 | — | — | US | claimed |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-06-02 | — | — | US | claimed |
| US-20160058771-A1 | ALPHA-2 ADRENOCEPTOR AND SIGMA RECEPTOR LIGAND COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-03-03 | — | — | US | claimed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | claimed |
| EP-2818166-A1 | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) | Laboratorios del Dr. Esteve S.A. (ES) | 2014-12-31 | — | — | EP | claimed |
| EP-2276744-B1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | ESTEVE LABOR DR (ES) | 2014-10-01 | — | — | EP | claimed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | claimed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | claimed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-12 | — | — | US | claimed |
| EP-2276744-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-01-26 | — | — | EP | claimed |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | claimed |
| US-7696199-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-13 | — | — | US | claimed |
| EP-2116539-A1 | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2009130310-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-29 | — | — | WO | claimed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, SLC6A2 | SIGMAR1 1/4885KMT2A 3362/4885MEN1 3111/4885 |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | OPRL1, NPSR1, SIGMAR1 | SIGMAR1 3/4885KMT2A 4695/4885MEN1 4818/4885 |
| US-20160058771-A1 | ALPHA-2 ADRENOCEPTOR AND SIGMA RECEPTOR LIGAND COMBINATIONS | ADRB2, ADRA2C, ADRA2A | SIGMAR1 7/4885KMT2A 2773/4885MEN1 4636/4885 |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, OPRM1 | SIGMAR1 1/4885KMT2A 4452/4885MEN1 4120/4885 |
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KMT2A 4113/4885MEN1 4579/4885 |
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885KMT2A 3202/4885MEN1 4877/4885 |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885KMT2A 3202/4885MEN1 4877/4885 |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885KMT2A 4286/4885MEN1 4669/4885 |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KMT2A 4113/4885MEN1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.